Trial · NCT07897955
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
NCT07897955, Not yet recruiting, Fujian Medical University Union Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models. Trials, record NCT07897955. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897955
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
- NCT number
- NCT07897955
- Status
- Not yet recruiting
- Enrollment
- 2,000 participants, estimated
- Lead sponsor
- Fujian Medical University Union Hospital
- Conditions
- Acute Ischemic Stroke
- Interventions
- tenecteplase
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Modified Rankin Scale Score at 90 Days | 90 days after tenecteplase administration (±7 days) | |
| Secondary | Proportion of Participants With an mRS Score of 0-2 at 90 Days | 90 days after tenecteplase administration (±7 days) | The percentage of participants with a modified Rankin Scale (mRS) score of 0-2 at 90 days. The mRS ranges from 0 to 6, with lower scores indicating better functional outcomes. A score of 0-2 indicates functional independence. |
| Secondary | Proportion of Participants With an mRS Score of 0-1 at 90 Days | 90 days after tenecteplase administration (±7 days) | The percentage of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days. A score of 0 indicates no symptoms, and a score of 1 indicates no significant disability despite symptoms. |
| Secondary | Change in NIHSS Score From Baseline to Day 7 or Discharge | Baseline to 7 days after tenecteplase administration (±2 days) or hospital discharge | Change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 7 or hospital discharge. The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment. A reduction in the score indicates neurological improvement. |
| Secondary | EQ-5D-5L Score at 90 Days | 90 days after tenecteplase administration (±7 days) | |
| Secondary | Incidence of Symptomatic Intracranial Hemorrhage Within 48 Hours | Within 48 hours after tenecteplase administration | |
| Secondary | All-Cause Mortality at 90 Days | Within 90 days after tenecteplase administration | |
| Secondary | Incidence of Asymptomatic Intracranial Hemorrhage Within 48 Hours | Within 48 hours after tenecteplase administration | |
| Secondary | Incidence of Non-Intracranial Bleeding Complications | From tenecteplase administration through 90 days | The percentage of participants who experience non-intracranial bleeding complications, including gastrointestinal bleeding, urinary tract bleeding, oral or nasal mucosal bleeding, and subcutaneous hematoma. |
| Secondary | Incidence of Non-Bleeding Serious Adverse Events | From tenecteplase administration through 90 days | The percentage of participants who experience non-bleeding serious adverse events, including cerebral herniation, pneumonia, respiratory failure, circulatory failure, stress ulcer, secondary epilepsy, urinary tract infection, sepsis, renal failure, acute coronary syndrome, venous thrombosis, or psychiatric symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897955
GET https://conductscience.org/api/trials/v1/NCT07897955/registered